What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol
Autor: | Fernando A. Bozza, Luis F. Reyes, Madiha Hashmi, Robert A. Fowler, Janet T Scott, Muge Cevik, Nazir I Lone, Natalie Elkheir, Lance Turtle, Jan Cato Holter, Annemarie B Docherty, Sulaiman Lakoh, Louise Sigfrid, Daniel Plotkin, Colin Berry, Ibrahim Richard Bangura, Malcolm G Semple, Edwin C. Jesudason, Gail Carson, J. Kenneth Baille, Carlo Palmieri, Thomas M Drake, Ewen M Harrison, Daniel Munblit, John H Amuasi, Katrina Hann, Anne Margarita Dyrhol-Riise, Wei Shen Lim, Hayley E Hardwick, Chloe Donohue, Clark D Russell, Joanne McPeake, Jordi Rello, Antonia Ho, Anna Beltrame, Anders Benjamin Kildal, David J Lowe |
---|---|
Přispěvatelé: | Institut Català de la Salut, [Sigfrid L] ISARIC Global Support Centre, Centre for Tropical Medicine and Global Heatlh, University of Oxford, Oxford, UK. [Cevik M] Infection and Global Health Division, School of Medicine, University of St Andrews, St Andrews, UK. [Jesudason E] Department of Rehabilitation Medicine, NHS Lothian, Edinburgh, UK. [Lim WS] Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK. [Rello J] Centro de Investigación Biomédica en Red – Enfermedades Respiratorias (CIBERES), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Research Department, CHU Nîmes, Université Nîmes- Montpellier, Nîmes, France. [Amuasi J] School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, Vall d'Hebron Barcelona Hospital Campus, University of St Andrews. School of Medicine, University of St Andrews. Infection and Global Health Division |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Longitudinal study
medicine.medical_treatment 030204 cardiovascular system & hematology Ghana law.invention Russia South Africa HV 0302 clinical medicine RA0421 law Risk Factors RA0421 Public health. Hygiene. Preventive Medicine HV Social pathology. Social and public welfare Other subheadings::/diagnosis [Other subheadings] virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] 030212 general & internal medicine Longitudinal Studies Prospective Studies Prospective cohort study COVID-19 (Malaltia) - Complicacions Rehabilitation Norway public health Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] 3rd-DAS General Medicine Intensive care unit 3. Good health Infectious Diseases Italy técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes::estudios longitudinales [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Medicine Covid-19 Psychosocial medicine.medical_specialty BF Psychology Otros calificadores::/diagnóstico [Otros calificadores] BF Colombia técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] 03 medical and health sciences SDG 3 - Good Health and Well-being medicine Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies::Longitudinal Studies [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Humans Intensive care medicine Protocol (science) business.industry Public health COVID-19 United Kingdom Observational study Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Mètode longitudinal business |
Zdroj: | BMJ Open Sigfrid, L, Cevik, M, Jesudason, E, Lim, W S, Rello, J, Amuasi, J, Bozza, F, Palmieri, C, Munblit, D, Holter, J C, Kildal, A B, Reyes, L F, Russell, C D, Ho, A, Turtle, L, Drake, T M, Beltrame, A, Hann, K, Bangura, I R, Fowler, R, Lakoh, S, Berry, C, Lowe, D J, McPeake, J, Hashmi, M, Dyrhol-Riise, A M, Donohue, C, Plotkin, D, Hardwick, H, Elkheir, N, Lone, N I, Docherty, A, Harrison, E, Baillie, J K, Carson, G, Semple, M G & Scott, J T 2021, ' What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol ', BMJ Open, vol. 11, no. 3, pp. e043887 . https://doi.org/10.1136/bmjopen-2020-043887 BMJ Open, Vol 11, Iss 3 (2021) Scientia |
ISSN: | 2044-6055 |
Popis: | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Malalties infeccioses; Salut pública Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Enfermedades infecciosas; Salud pública Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Infectious diseases; Public health Introduction Very little is known about possible clinical sequelae that may persist after resolution of acute COVID-19. A recent longitudinal cohort from Italy including 143 patients followed up after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60-day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical intensive care unit patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness. The primary aim of this study is to characterise physical and psychosocial sequelae in patients post-COVID-19 hospital discharge. Methods and analysis This is an international open-access prospective, observational multisite study. This protocol is linked with the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) and the WHO’s Clinical Characterisation Protocol, which includes patients with suspected or confirmed COVID-19 during hospitalisation. This protocol will follow-up a subset of patients with confirmed COVID-19 using standardised surveys to measure longer term physical and psychosocial sequelae. The data will be linked with the acute phase data. Statistical analyses will be undertaken to characterise groups most likely to be affected by sequelae of COVID-19. The open-access follow-up survey can be used as a data collection tool by other follow-up studies, to facilitate data harmonisation and to identify subsets of patients for further in-depth follow-up. The outcomes of this study will inform strategies to prevent long-term consequences; inform clinical management, interventional studies, rehabilitation and public health management to reduce overall morbidity; and improve long-term outcomes of COVID-19. Ethics and dissemination The protocol and survey are open access to enable low-resourced sites to join the study to facilitate global standardised, longitudinal data collection. Ethical approval has been given by sites in Colombia, Ghana, Italy, Norway, Russia, the UK and South Africa. New sites are welcome to join this collaborative study at any time. Sites interested in adopting the protocol as it is or in an adapted version are responsible for ensuring that local sponsorship and ethical approvals in place as appropriate. The tools are available on the ISARIC website (www.isaric.org). Protocol registration number osf.io/c5rw3/ Protocol version 3 August 2020 EuroQol ID 37035. This work was supported by the Department for International Development and Wellcome (215091/Z/18/Z) and the Bill & Melinda Gates Foundation (OPP1209135). CP would like to acknowledge the support of the Liverpool Experimental Cancer Medicine Centre (Grant Reference: C18616/A25153) and The Clatterbridge Cancer Centre Charity. CB acknowledges the support from British Heart Foundation RE/18/6134217. LS would like to acknowledge the support of PREPARE funded by the European Commission’s FP7 Programme grant number 602525. |
Databáze: | OpenAIRE |
Externí odkaz: |